Celanese Corp. Q3 2008 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2008. Celanese Corporation is a global integrated chemical and advanced materials company. The financial statements are presented on an unaudited basis in accordance with US GAAP, separating continuing and discontinued operations.
Key Financial Metrics
| Metric | Q3 2008 | Q3 2007 | 9M 2008 | 9M 2007 |
|---|---|---|---|---|
| Net Sales | $1,823 million | $1,573 million | $5,537 million | $4,684 million |
| Gross Profit | $333 million (18.3%) | $337 million (21.4%) | $1,147 million (20.7%) | $1,033 million (22.1%) |
| Operating Profit | $151 million | $147 million | $592 million | $424 million |
| Net Earnings (Continuing Ops) | $164 million | $130 million | $512 million | $128 million |
| Net Earnings (Total) | $158 million | $128 million | $437 million | $212 million |
| Diluted EPS (Total) | $0.97 | $0.76 | $2.63 | $1.23 |
| Cash & Equivalents | $584 million | (As of Dec 31, 2007: $825 million) | ||
| Total Debt | $3,620 million | (As of Dec 31, 2007: $3,556 million) | ||
| Operating Cash Flow (9M) | $345 million | $279 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 16% in Q3 and 18% for the nine months ended Sept 30, 2008, compared to 2007. Growth was driven by higher prices (passing through raw material costs) and favorable foreign currency effects. Volume increases were noted in Acetyl Intermediates due to higher acetic acid availability compared to the 2007 outage period.
- Margin Compression: Gross profit margin declined from 21.4% to 18.3% in Q3 2008. Rising raw material and energy costs outpaced price increases during the quarter, though the nine-month gross profit increased by $114 million due to strong volumes and pricing earlier in the year.
- Discontinued Operations: The nine-month 2008 results include a significant loss of $75 million from discontinued operations, primarily due to a $107 million legal settlement regarding legacy polyester staple fiber antitrust litigation. In contrast, 2007 included gains from the sale of oxo products businesses.
- Other Charges: Q3 2008 included a $21 million asset impairment charge related to the Pampa, Texas facility, partially offset by $23 million in insurance recoveries from the 2007 Clear Lake outage and an $8 million gain from the release of Sorbates antitrust reserves.
Guidance, Outlook, and Risks
- Outlook: Management anticipates lower overall sales volumes through the end of 2008 due to economic slowdowns in North America and Europe, particularly in automotive and housing sectors. Signs of slowing growth in Asia linked to the global credit crisis were also noted.
- Capital Allocation: The company repurchased 9.76 million shares for $378 million during the first nine months of 2008 under a $400 million authorization. Capital expenditures for 2008 are expected to be approximately $290 million.
- Liquidity: The company maintains $650 million in available borrowing capacity under its revolving credit facility. Management believes resources are sufficient to meet liquidity requirements for the remainder of 2008 and the subsequent twelve months.
- Risks: Key risks include volatility in raw material prices (methanol, natural gas, ethylene), regulatory changes regarding chemicals (specifically Vinyl Acetate Monomer in Canada and EU), and potential liability from pending litigation. The company has no material direct exposure to Lehman Brothers Holdings, Inc.
Investor Verification Checklist
- Asset Impairment: Verify the status and future cash flow projections for the Pampa, Texas facility following the $21 million impairment charge.
- Legal Settlements: Confirm the finality of the $107 million polyester staple antitrust settlement and assess any remaining exposure in related litigation.
- Margin Sustainability: Monitor the ability to pass through rising energy and raw material costs to customers given the reported margin compression in Q3.
- Discontinued Ops: Review the specific components of the $75 million loss in discontinued operations to ensure no recurring charges are hidden within continuing operations.
- China Expansion: Track the operational ramp-up and cost recovery of the new Nanjing, China complex facilities (acetic acid, VAM, GUR).